Search

Glaukos Corp

Gesloten

SectorGezondheidszorg

178.53 -3.4

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

177.65

Max

185.06

Belangrijke statistieken

By Trading Economics

Inkomsten

1.4M

-18M

Verkoop

35M

186M

EPS

-0.14

Winstmarge

-9.901

Werknemers

1,094

EBITDA

-1.6M

-6.9M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+9.08% upside

Dividenden

By Acuity

Volgende Winsten

28 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.5B

10B

Vorige openingsprijs

181.93

Vorige sluitingsprijs

178.53

Nieuwssentiment

By Acuity

50%

50%

135 / 339 Rangschikking in Healthcare

Glaukos Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 sep 2026, 20:07 UTC

Glaukos Corp shares are higher today, recovering from an early dip amid speculation of a potential interest rate hike following a strong jobs report.

1 sep 2026, 19:31 UTC

Glaukos Corp. shares are lower today amid broader market volatility and rising U.S. Treasury yields, continuing a three-session decline.

31 aug 2026, 20:07 UTC

Glaukos Corp shares are lower amid broader market concerns over inflation and potential Fed rate hikes. Earlier, the stock rebounded from a session low.

28 aug 2026, 20:07 UTC

Glaukos Corp shares are lower during Friday's session amid rising U.S. Treasury yields and broader market trends, with no specific company news identified.

27 aug 2026, 20:07 UTC

Glaukos Corp. shares are higher amid broader market trends. A decline in initial jobless claims may support a positive outlook for health care stocks.

25 aug 2026, 20:07 UTC

Glaukos Corp shares are lower today amid broader market declines, despite remaining above their 20-day moving average and near the top of their one-month range.

21 aug 2026, 19:56 UTC

Glaukos Corp's shares are higher today, reflecting a cumulative gain since Thursday. The stock remains near the upper end of its one-month range.

20 aug 2026, 20:06 UTC

Glaukos Corp. shares are lower today, reflecting a decline from Wednesday's close. The stock earlier pulled back after reaching a session high.

19 aug 2026, 20:06 UTC

News

Glaukos Corp will present at the Wells Fargo Healthcare Conference on September 9, 2026, as shares gain during Wednesday's trading session.

14 aug 2026, 19:46 UTC

Glaukos Corp. shares are lower today, reaching a session low amid broader market declines following a surprise drop in U.S. retail sales for July.

13 aug 2026, 19:22 UTC

Glaukos Corp. shares are higher today amid unusually high trading volume. The stock remains significantly above its 20-day moving average.

12 aug 2026, 19:16 UTC

Glaukos Corp shares are higher today, supported by overall strength in U.S. stocks and positive quarterly results from AI sector companies.

10 aug 2026, 20:06 UTC

Glaukos Corp shares are higher today, following a broader market trend since Friday. Earlier, the stock reached a session high before pulling back.

7 aug 2026, 20:02 UTC

Glaukos Corp shares are rising in Friday's session, supported by unusually high trading volume and a steady upward trend since Thursday's close.

4 aug 2026, 19:36 UTC

Glaukos Corp shares are lower today, impacted by declines in the Health Care Equipment sub-sector. The stock pulled back after reaching an earlier high.

3 aug 2026, 20:06 UTC

Glaukos Corp shares are higher amid positive market sentiment, with the S&P 500 and Nasdaq 100 also gaining. The stock remains above its 20-day moving average.

31 jul 2026, 19:45 UTC

News

Glaukos shares are lower today despite H.C. Wainwright raising the price target to $195 from $168. Trading volume has been unusually high.

30 jul 2026, 21:31 UTC

News

Glaukos Corp shares are lower in after-market trading, tracking declines in the Health Care Equipment sector. UBS raised its price target to $172.

29 jul 2026, 21:22 UTC

Social Media
News

Glaukos Corp reported record net sales of $185.6 million in Q2 2026, raising its full-year revenue guidance to $680 million to $700 million. Shares are higher in after-market trading.

28 jul 2026, 17:46 UTC

News

Glaukos Corp shares are lower after UBS initiated coverage with a Neutral rating, overshadowing Stifel's Buy rating and $175 price target.

27 jul 2026, 19:16 UTC

Glaukos Corp shares are lower today, despite an initial gain. Broader market trends are affected by a significant drop in oil prices.

24 jul 2026, 19:56 UTC

Glaukos Corp. shares are trading higher today, maintaining a cumulative gain since Thursday and remaining above their 20-day moving average.

21 jul 2026, 17:41 UTC

Glaukos Corp shares are lower today amid a decline in the Health Care Equipment sub-sector, reversing the recent trend of higher daily closes.

Peer Vergelijking

Prijswijziging

Glaukos Corp Prognose

Koersdoel

By TipRanks

9.08% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 193.58 USD  9.08%

Hoogste 225 USD

Laagste 165 USD

Gebaseerd op 13 Wall Street-analisten die 12-maands prijsdoelen bieden voor Glaukos Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

13 ratings

12

Buy

1

Hold

0

Sell

Sentiment

By Acuity

135 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat